Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Effects of inhibition of nitric oxide synthesis in patients with coronary artery disease and stable angina
Cardiology Units, Hippokration Hospital, Athens University Medical School, Hammersmith Hospital London, U.K.
revised 25 June 1996; accepted 2 July 1996.
Correspondence: Dimitris Tousoulis MD, Cardiology Unit, Hammersmith Hospital, Du Cane Road, London W12 0NN, U.K.
Abstract
AIMS: Inhibition of nitric oxide synthesis causes a decrease in the basal diameter of normal distal epicardal coronary arteries in normal subjects. The effects of inhibition of nitric oxide in atheromatous coronary arteries is unknown. This study assessed the effects of the inhibition of nitric oxide synthesis in epicardial coronary arteries in patients with coronary artery disease.
METHODS AND RESULTS: The effects of an intracoronary infusion of NG-monomethyl-L-arginine (LNMMA, an inhibitor of nitric oxide synthesis), were studied in 13 patients with chronic stable angina and coronary artery disease. The diameter of angiographically normal proximal and distal segments and coronary stenoses was measured by quantitative angiography. In response to an LNMMA infusion of 16 µmol min1 for 4 min there was a significant reduction (P<0·01) in the luminal diameter of the distal segments of diseased arteries (from 1·32 ± 0·07 to 1·17 ± 0·06 mm) and at the site of stenosis (from 1·15 ± 0·22 to 1·06 ± 0·20 mm), but no change (P=NS) in the luminal diameter of the proximal segments (from 3·16 ± 0·12 to 3·08 ± 0·14 mm) of diseased arteries.
CONCLUSIONS: The average effect of inhibition of basal nitric oxide synthesis in epicardial coronary arteries in patients with stable angina and coronary artery disease was only distal constriction. Coronary stenoses constricted at the highest LNMMA concentration.
Key Words: Endothelium nitric oxide coronary artery disease endothelium-derived relaxing factor
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF] |
||||
![]() |
D Tousoulis, G J Davies, T Crake, and P C Toutouzas Vasomotion and nitric oxide bioactivity in diseased coronary arteries Heart, April 1, 2002; 87(4): 320 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Tousoulis, G J Davies, C Tentolouris, G Goumas, C Stefanadis, and P Toutouzas Vasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaque Heart, September 1, 2001; 86(3): 296 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Tousoulis, C Tentolouris, T Crake, G Goumas, C Stefanadis, P Toutouzas, and G Davies Complex stenosis morphology and vasomotor responses to inhibition of nitric oxide synthesis Heart, November 1, 2000; 84(5): 529 - 534. [Abstract] [Full Text] |
||||
![]() |
D Tousoulis, C Tentolouris, T Crake, C Stefanadis, P Toutouzas, and G Davies Evidence of partially preserved endothelial dilator function in diseased coronary arteries Heart, October 1, 1999; 82(4): 471 - 476. [Abstract] [Full Text] [PDF] |
||||

